MyAverix Finance
HK · Healthcare
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (1349)
Drug Manufacturers - Specialty & Generic
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (1349) is listed on HK in the Healthcare sector. Industry: Drug Manufacturers - Specialty & Generic. As of 2026-05-21, reported market cap is $2.77B, P/E ratio is 18.00, net margin is -23.3%. Use this page for a quick overview, then open the MyAverix Finance app for income statements, balance sheet, cash flow, and news.
Key metrics for 1349
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (1349) — FAQ
What is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd's market cap?
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (1349) has a reported market cap of $2.77B (data as of 2026-05-21).
What is 1349's P/E ratio?
The price-to-earnings (P/E) ratio for Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (1349) is 18.00 (data as of 2026-05-21).
Does Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd pay a dividend?
Dividend yield is not available in the current snapshot for Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (1349). Check the MyAverix Finance app for the latest dividend data.
What sector is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd in?
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (1349) is classified in the Healthcare sector (Drug Manufacturers - Specialty & Generic industry).
What exchange is 1349 listed on?
1349 is listed on HK.
What is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd's net margin?
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (1349) reports a net margin of -23.3% (data as of 2026-05-21).
Full report in the app
Get the full report in the MyAverix Finance app — income, balance sheet, cash flow, ratios, and multi-year trends in one place.